Immune checkpoint inhibitors continue to revolutionize the treatment of a wide range of solid-tumor and hematological malignancies, with a growing list of approvals and label expansions. The Immune…
Despite the extensive armamentarium of chronic pain therapies, which is increasingly subject to generic competition, the chronic pain market continues to represent a notable commercial…
The lucrative EU5 rheumatoid arthritis market is dominated by biologics, including five tumor necrosis factor (TNF)-α inhibitors and four biologics with alternative mechanisms of action. The TNF…
Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease that usually affects children but can persist or start in adulthood. For many years, the treatment landscape has remained…
NSCLC is one of the most dynamic indications in oncology. In the United States, the FDAapproved six new therapies for NSCLC in 2015 and, in 2016, granted approval to Tecentriq (Roche/Genentech…
Chronic myeloid leukemia is a slow progressive tumor, characterized by different phases of disease (chronic, accelerated, and blast). Treatment of chronic myeloid leukemia is dominated by oral BCR-…
Painful diabetic neuropathy (PDN), a subset of diabetic neuropathy; affects approximately seven million people in the United States and major European markets. The primary goal of treating PDN is…
Hormonal therapy is the mainstay of prostate cancer, in all stages of disease and clinical settings. The adoption of novel hormonal agents, Zytiga (Johnson & Johnson/Janssen) and Xtandi (Pfizer/…
Dermatologists have many years of experience with the tumor necrosis factor-alpha (TNF-α) inhibitors Humira (AbbVie) and Enbrel (Pfizer) as first-line biologics for the treatment of psoriasis…
IBS-D is a highly prevalent disorder regularly encountered in general practice that is marked by excessive defecation and abdominal pain/discomfort. Currently, its etiology and pathophysiology are…
The tumor necrosis factor (TNF) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. However, several…
Once limited to ankylosing spondylitis (AS), the axial spondyloarthritis (AxSpA) therapy market is undergoing rapid change as the definition of the disease expands beyond those with detectable…
Because no current therapy for type 2 diabetes offers disease-modifying capabilities, there is high unmet need for drugs that can effectively control the disease. DRG’s Type 2 Diabetes Unmet…
Following the European Medicines Agency’s approvals of the PDE-4 inhibitor Otezla and the IL-17 inhibitor Cosentyx for psoriatic arthritis (PsA), treatment of this disease in the EU5 has begun to…
The relatively recent FDA approvals of tedizolid (Merck’s Sivextro), dalbavancin (Allergan’s Dalvance), and oritavancin (The Medicines Company’s Orbactiv) for the treatment of acute bacterial…